Valuation: Ovid Therapeutics Inc.

Market Cap 54Cr 46Cr 43Cr 39Cr 74Cr 5.12TCr 75Cr 506.73Cr 197.61Cr 2.57TCr 200.93Cr 196.56Cr 8.51TCr P/E 2026 *
-7.27x
P/E 2027 * -6.63x
Enterprise Value 54Cr 46Cr 43Cr 39Cr 74Cr 5.12TCr 75Cr 506.73Cr 197.61Cr 2.57TCr 200.93Cr 196.56Cr 8.51TCr EV / Sales 2026 *
637x
EV / Sales 2027 * 2,396x
Free-Float
93.28%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ovid Therapeutics Inc.

1 day+1.64%
1 week-1.59%
Current month+25.45%
1 month+15.56%
3 months+14.14%
6 months+92.07%
Current year+70.86%
1 week 2.71
Extreme 2.71
2.95
1 month 2.2
Extreme 2.2
2.95
Current year 1.36
Extreme 1.36
3.1
1 year 0.94
Extreme 0.94
3.1
3 years 0.24
Extreme 0.2425
4.14
5 years 0.24
Extreme 0.2425
4.14
10 years 0.24
Extreme 0.2425
15.93
Manager TitleAgeSince
Chief Executive Officer 45 01/01/2026
Director of Finance/CFO 59 06/07/2026
Chief Tech/Sci/R&D Officer 60 02/12/2025
Director TitleAgeSince
Chairman 72 01/04/2014
Director/Board Member 81 23/11/2015
Director/Board Member 61 14/06/2017
Date Insider Type Main position Quantity % Market Cap.
06/07/26 Free

Chief Financial Officer

50,000 0.0268%
06/07/26 Other

Chief Financial Officer

4,50,625 0.2414%
07/04/26 Free

Director

17,578 0.0133%
Change 5-day change 1-year change 3-year change Capi.($)
+1.64%-1.59%+191.01%-29.22% 54Cr
-3.00%+0.33%+77.39%+109.41% 7.4TCr
+1.90%+23.53%+56.60%+97.76% 6.47TCr
+1.48%+2.57%-4.28%+476.93% 2.73TCr
+5.06%+25.03%+5.07%-0.97% 2.79TCr
+2.74%+11.55%+66.56%+27.34% 2.6TCr
+0.47%+6.12%+36.66%-13.79% 2TCr
+1.82%-3.11%+245.72%+423.83% 1.78TCr
+0.94%+2.38%+24.83%+552.12% 1.62TCr
+1.81%+6.31%+40.73%+154.91% 1.33TCr
Average +1.51%+5.33%+74.03%+179.83% 2.88TCr
Weighted average by Cap. +0.84%+6.64%+60.14%+161.38%

Financials

2026 *2027 *
Net sales 8L 7L 7L 6L 11.57L 8.04Cr 11.73L 79.6L 31.04L 4.04Cr 31.56L 30.88L 13Cr 2L 2L 2L 2L 3L 2.14Cr 3L 21.15L 8L 1.07Cr 8L 8L 3.55Cr
Net income -6.86Cr -5.88Cr -5.5Cr -5.04Cr -9.45Cr -656.64Cr -9.57Cr -65Cr -25Cr -329.86Cr -26Cr -25Cr -1.09TCr -8.35Cr -7.16Cr -6.69Cr -6.13Cr -12Cr -799.2Cr -12Cr -79Cr -31Cr -401.47Cr -31Cr -31Cr -1.33TCr
Net Debt - -
Logo Ovid Therapeutics Inc.
Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
Employees
23
Date Price Change Volume
21/26/21 $2.785 +1.64% 4,58,889
20/26/20 $2.740 -6.48% 11,46,456
19/26/19 $2.930 +3.17% 28,75,502
18/26/18 $2.840 -1.73% 19,35,255
17/26/17 $2.890 +2.12% 17,47,954
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2.740USD
Average target price
5.693USD
Spread / Average Target
+107.79%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OVID Stock